17 research outputs found
Adipokinesand Ghrelin Rolein Regulation of Ovarian Function in Obesity
There is a great worldwide trend in the incidence of obesity, which is increasing with each passing year among all populations, including women of reproductive age. Given the impressive list of diseases associated with obesity, as well as the negative inverse correlation of the severity of obesity with fertility, this problem is global not only in the social sphere, but it also becomes demographically significant.Along with other pathogenetic mechanisms leading to persistent anovulation, an imbalance in adipokine production by adipose tissue can also serve as one of the important links in the development of reproductive dysfunction. Despite apparent interest in this topic, a large number of previously discovered adipokines are still not studied. Among adipokines, the effects of adiponectin and leptin on reproductive function are best known. Alterations in adiponectin and leptin levels can affect hypothalamic-pituitary-gonadal signaling, folliculogenesis, oogenesis and steroidogenesis. In addition, leptin is involved in the initiation of puberty, regulation of the menstrual cycle, and changes the balance between proliferation and apoptosis in ovarian cells. The leading causes of reduced fertility, infertility, and IVF failure in obese patients are mechanisms that promote the formation of chronic anovulation, delay the maturation of oocytes, reduce their quality, and/or lead to changes in endometrial susceptibility. These effects can be caused by an imbalance in the concentrations of leptin and adiponectin (leptin excess and adiponectin deficiency), lead to endometrial dysfunction, disruption of implantation and early embryogenesis. These changes, in turn, can affect just as the likelihood of spontaneous conception, so the effectiveness of assisted reproductive technologies and subsequent gestation.Thus, the study of potential pathogenetic pathways of fertility regulation in obesity, one of which is the subject of this review, is an important area for further study
THE PREVENTION, DIAGNOSIS, AND TREATMENT OF VITAMIN D AND CALCIUM DEFICIENCIES IN THE ADULT POPULATION OF RUSSIA AND IN PATIENTS WITH OSTEOPOROSIS (ACCORDING TO THE MATERIALS OF PREPARED CLINICAL RECOMMENDATIONS)
The paper presents data on the role of vitamin D and calcium in the function of many human organs and tissues.Β Lifestyle, dietary preferences, and insufficient physical activity contribute to the high prevalence of vitamin D and calciumΒ deficiencies in the adult population of Russia, causing different diseases and abnormalities. The authors haveΒ worked out recommendations for the preventive use of vitamin D and calcium in healthy population, give consumptionΒ rates for these substances, and describe the clinical and laboratory signs of vitamin D deficiency and indicationsΒ for screening. They also propose treatment regimens for vitamin D deficiency and depict the signs of intoxication inoverdose. Particular emphasis is laid on the place of vitamin D and calcium in the therapy of osteoporosis
Pneumonia in pregnant women with covid-19: Is it a new thrombotic microangiopathy in obstetric practice?
Thrombotic microangiopathies during pregnancy and puerperium are rare and, if undiagnosed, can be life-threating conditions for both the mother and the baby. The aim of this review article is to briefly describe clinical profile and highlight the clues for a correct diagnosis of pregnancy-related thrombotic microangiopathies. Of particular interest and important practical significance are the presented data on changes in the hemostatic system in patients with a new coronavirus infection COVID-19 through the prism of thrombotic microangiopathies
VITAMIN D I GESTATsIONNYE RISKI
Π ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ Π³ΠΎΠ΄Ρ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΡΡΡ Π΄Π΅ΡΠΈΡΠΈΡΠ° ΠΈ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D Π²ΡΡΠΎΠΊΠ°. Π‘ΡΠ΅Π΄ΠΈ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
ΠΎΠ½Π° ΡΠΎΡΡΠ°Π²Π»ΡΠ΅Ρ ΠΎΡ 37 Π΄ΠΎ 79%. ΠΠ·Π²Π΅ΡΡΠ½ΠΎ, ΡΡΠΎ Π΄Π΅ΡΠΈΡΠΈΡ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½ Ρ ΡΠΈΡΠΊΠΎΠΌ ΡΠ°Π·Π²ΠΈΡΠΈΡ Π½Π΅Π²ΡΠ½Π°ΡΠΈΠ²Π°Π½ΠΈΡ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ, ΠΏΡΠ΅ΡΠΊΠ»Π°ΠΌΠΏΡΠΈΠ΅ΠΉ, Π³Π΅ΡΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΡΠ°Ρ
Π°ΡΠ½ΠΎΠ³ΠΎ Π΄ΠΈΠ°Π±Π΅ΡΠ°, Π±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π²Π°Π³ΠΈΠ½ΠΎΠ·Π°, ΡΠΈΠ½Π΄ΡΠΎΠΌ Π·Π°Π΄Π΅ΡΠΆΠΊΠΈ ΡΠΎΡΡΠ° ΠΏΠ»ΠΎΠ΄Π°, Ρ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΡΠΌ ΡΠΈΡΠΊΠΎΠΌ ΡΠΎΠ΄ΠΎΡΠ°Π·ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΏΡΡΠ΅ΠΌ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠΈ ΠΊΠ΅ΡΠ°ΡΠ΅Π²Π° ΡΠ΅ΡΠ΅Π½ΠΈΡ. Π¦Π΅Π»ΡΡ Π½Π°ΡΡΠΎΡΡΠ΅Π³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ²ΠΈΠ»Π°ΡΡ ΠΎΡΠ΅Π½ΠΊΠ° ΡΠ°ΡΡΠΎΡΡ Π²ΡΡΡΠ΅ΡΠ°Π΅ΠΌΠΎΡΡΠΈ Π΄Π΅ΡΠΈΡΠΈΡΠ° ΠΈ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D Ρ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
Ρ Π±Π΅ΡΠΏΠ»ΠΎΠ΄ΠΈΠ΅ΠΌ, Π½Π΅Π²ΡΠ½Π°ΡΠΈΠ²Π°Π½ΠΈΠ΅ΠΌ, ΠΏΡΠ΅ΡΠΊΠ»Π°ΠΌΠΏΡΠΈΠ΅ΠΉ ΠΈ Π³Π΅ΡΡΠ°ΡΠΈΠΎΠ½Π½ΡΠΌ ΡΠ°Ρ
Π°ΡΠ½ΡΠΌ Π΄ΠΈΠ°Π±Π΅ΡΠΎΠΌ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠΎΠ³ΠΎΡΡΠ½ΠΎΠ΅ ΡΠ΅ΡΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ΅ ΠΈ ΠΏΡΠΎΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅, Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΎ Π½Π° Π±Π°Π·Π΅ Π€ΠΠΠ£ Β«Π‘ΠΠ€ΠΠΠ¦ ΠΈΠΌ. Π.Π. ΠΠ»ΠΌΠ°Π·ΠΎΠ²Π°Β». ΠΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΎ 800 Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
ΠΆΠ΅Π½ΡΠΈΠ½ Ρ ΡΠ΅Π½ΡΡΠ±ΡΡ 2013 Π³ ΠΏΠΎ ΠΌΠ°ΡΡ 2015 Π³, ΠΏΡΠΎΠΆΠΈΠ²Π°ΡΡΠΈΡ
Π² Π‘Π°Π½ΠΊΡ-ΠΠ΅ΡΠ΅ΡΠ±ΡΡΠ³Π΅ ΠΈ ΠΠ΅Π½ΠΈΠ½Π³ΡΠ°Π΄ΡΠΊΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ. Π‘ΡΠ΅Π΄Π½ΠΈΠΉ Π²ΠΎΠ·ΡΠ°ΡΡ 29Β±2,1 Π»Π΅Ρ, ΡΡΠΎΠΊ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ 12-14, 24-36, 34-38 Π½Π΅Π΄Π΅Π»Ρ. ΠΡΠ΅ΠΌ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΡΠΌ ΠΏΡΠΎΠΈΠ·Π²Π΅Π΄Π΅Π½ Π·Π°Π±ΠΎΡ Π±ΠΈΠΎΠΎΠ±ΡΠ°Π·ΡΠΎΠ² ΠΊΡΠΎΠ²ΠΈ Ρ ΠΏΠΎΡΠ»Π΅Π΄ΡΡΡΠΈΠΌ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ΠΌ ΡΡΠΎΠ²Π½Ρ 25-Π³ΠΈΠ΄ΡΠΎΠΊΡΠΈ-ΠΊΠ°Π»ΡΡΠΈΡΠ΅ΡΠΎΠ»Π° (25-OH-D) ΡΠ»Π΅ΠΊΡΡΠΎΡ
Π΅ΠΌΠΈΠ»ΡΠΌΠΈΠ½Π΅ΡΡΠ΅Π½ΡΠ½ΡΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Π½Π° Π°Π½Π°Π»ΠΈΠ·Π°ΡΠΎΡΠ΅ Architect 2000. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ: Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡ ΠΈ Π΄Π΅ΡΠΈΡΠΈΡ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D Π²ΡΡΠ²Π»Π΅Π½Ρ Ρ 100% ΠΆΠ΅Π½ΡΠΈΠ½ Ρ Π±Π΅ΡΠΏΠ»ΠΎΠ΄ΠΈΠ΅ΠΌ (Π² ΡΠΎΠ»Π»ΠΈΠΊΡΠ»ΡΡΠ½ΠΎΠΉ ΠΆΠΈΠ΄ΠΊΠΎΡΡΠΈ Ρ 80% ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ, Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ Ρ 100%). ΠΡΠΈ ΡΠ³ΡΠΎΠ·Π΅ ΠΏΡΠ΅ΡΡΠ²Π°Π½ΠΈΡ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ Π² I ΡΡΠΈΠΌΠ΅ΡΡΡΠ΅ Π΄Π΅ΡΠΈΡΠΈΡ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ Π²ΡΡΠ²Π»Π΅Π½ Ρ 47,9% Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
, Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡ - Ρ 22,9%, Π½ΠΎΡΠΌΠ° Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D - Ρ 29,2%. Π§Π°ΡΡΠΎΡΠ° Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ Π΄Π΅ΡΠΈΡΠΈΡΠ° Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D Ρ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
Ρ ΠΏΡΠ΅ΡΠΊΠ»Π°ΠΌΠΏΡΠΈΠ΅ΠΉ ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 69,6%, Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΠΈ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D - 21,5%, Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΡΠΎΠ²Π½Ρ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D -8,9%. ΠΡΠΈ ΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠΎΡΠ΅ΠΊΠ°ΡΡΠ΅ΠΉ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ Π΄Π΅ΡΠΈΡΠΈΡ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ Π½Π΅ Π±ΡΠ», Ρ 18,5% ΠΆΠ΅Π½ΡΠΈΠ½ Π²ΡΡΠ²Π»Π΅Π½Π° Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D, Ρ 81,5% ΠΆΠ΅Π½ΡΠΈΠ½ - Π½ΠΎΡΠΌΠ°Π»ΡΠ½ΡΠΉ ΡΡΠΎΠ²Π΅Π½Ρ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D. Π‘Π²ΡΠ·Ρ ΠΌΠ΅ΠΆΠ΄Ρ Π΄Π΅ΡΠΈΡΠΈΡΠΎΠΌ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D ΠΈ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ΠΌ Π³Π΅ΡΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΡΠ°Ρ
Π°ΡΠ½ΠΎΠ³ΠΎ Π΄ΠΈΠ°Π±Π΅ΡΡ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½Π° Π½Π΅ Π±ΡΠ»Π°. ΠΡΠ²ΠΎΠ΄Ρ. Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡ ΠΈ Π΄Π΅ΡΠΈΡΠΈΡ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D Π²ΡΡΡΠ΅ΡΠ°Π΅ΡΡΡ Ρ 100% ΠΆΠ΅Π½ΡΠΈΠ½ Ρ Π±Π΅ΡΠΏΠ»ΠΎΠ΄ΠΈΠ΅ΠΌ, Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ Ρ Π½Π΅Π²ΡΠ½Π°ΡΠΈΠ²Π°Π½ΠΈΡ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ Π΄Π΅ΡΠΈΡΠΈΡ ΠΈ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D Π²ΡΡΡΠ΅ΡΠ°Π΅ΡΡΡ Π² 6 ΡΠ°Π· ΡΠ°ΡΠ΅, Ρ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ
Ρ ΠΏΡΠ΅ΡΠΊΠ»Π°ΠΌΠΏΡΠΈΠ΅ΠΉ Π² 5 ΡΠ°Π· ΡΠ°ΡΠ΅ Π²ΡΡΡΠ΅ΡΠ°Π΅ΡΡΡ Π½ΠΈΠ·ΠΊΠΈΠΉ ΡΡΠΎΠ²Π΅Π½Ρ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D. ΠΡΠΈ ΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠΎΡΠ΅ΠΊΠ°ΡΡΠ΅ΠΉ Π±Π΅ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΡΡΠΈ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D Π²ΡΡΠ²Π»Π΅Π½Π° Π»ΠΈΡΡ Ρ 18,5% ΠΆΠ΅Π½ΡΠΈΠ½, Π΄Π΅ΡΠΈΡΠΈΡ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° D Π²ΡΡΠ²Π»Π΅Π½ Π½Π΅ Π±ΡΠ»
Dozozavisimyy effekt vliyaniya potrebleniyakal'tsiya na fosforno-kal'tsievyy i kostnyyobmeny pri beremennosti
The influence of calcium intake during pregnancy on calcium
and phosphorus metabolism, bone turnover and BMD in postpartum
period was investigated in 35 healthy pregnant women.
The control group included 40 healthy women of reproductive
age. In women with the consumption less than 800 mg of calcium
in the III trimester of pregnancy there was decrease of
calcium excretion by the kidney. In both subgroups of pregnant
bone turnover markers showed increased metabolism in bone
tissue in 1,3-1,5 times in comparison with control group. Measurement
of the BMD made on 4-6 day postpartum period. In
the lumbar spine and distal forearm osteopenia was diagnosed
in 2,5 and 1,5 times more frequently than in the control group
(
OTsENKA VSTREChAEMOSTI ALLEL'NYKh VARIANTOV GENA RETsEPTORA KAL'TsITONINA U ZhENShchIN SO SNIZhENNOY MPK PRI GIPOESTROGENEMII
ΠΡΠΎΠ²ΠΎΠ΄ΠΈΠ»Π°ΡΡ ΠΎΡΠ΅Π½ΠΊΠ° Π²ΡΡΡΠ΅ΡΠ°Π΅ΠΌΠΎΡΡΠΈ Π³Π΅Π½ΠΎΡΠΈΠΏΠΎΠ² ΠΈ Π°Π»Π»Π΅Π»Π΅ΠΉ Π³Π΅Π½Π° ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ° ΠΊΠ°Π»ΡΡΠΈΡΠΎΠ½ΠΈΠ½Π° Ρ ΠΆΠ΅Π½ΡΠΈΠ½ ΡΠΎ ΡΠ½ΠΈΠΆΠ΅Π½Π½ΠΎΠΉ ΠΠΠ Π² ΠΏΠΎΡΡΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π°Π»ΡΠ½ΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅ ΠΈ ΠΏΠΎΡΠ»Π΅ ΠΎΠ²Π°ΡΠΈΠΎΡΠΊΡΠΎΠΌΠΈΠΈ. ΠΠ·ΡΡΠ°Π»ΡΡ ΠΏΠΎΠ»ΠΈΠΌΠΎΡΡΠΈΠ·ΠΌ Π΄Π°Π½Π½ΠΎΠ³ΠΎ Π³Π΅Π½Π° Π² Π³ΡΡΠΏΠΏΠ°Ρ
Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΡΠΊΠΎΡΠΎΡΡΠΈ ΠΊΠΎΡΡΠ½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π° ΠΏΡΠΈ Π³ΠΈΠΏΠΎΡΡΡΡΠΎΠ³Π΅Π½Π΅ΠΌΠΈΠΈ, ΠΊΠΎΡΠΎΡΠ°Ρ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»Π°ΡΡ Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Π΄Π΅Π·ΠΎΠΊΡΠΈΠΏΠΈΡΠΈΠ΄ΠΈΠ½ΠΎΠ»ΠΈΠ½Π° ΠΈ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΡ ΠΠΠ Π·Π° 12 ΠΌΠ΅ΡΡΡΠ΅Π² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ. Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠΉ ΡΠ°Π·Π½ΠΈΡΡ Π² ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠΈ Π°Π»Π»Π΅Π»ΡΠ½ΡΡ
Π²Π°ΡΠΈΠ°Π½ΡΠΎΠ² Π³Π΅Π½Π° ΠΊΠ°Π»ΡΡΠΈΡΠΎΠ½ΠΈΠ½Π° Ρ ΠΆΠ΅Π½ΡΠΈΠ½ Ρ Π²ΡΡΠΎΠΊΠΎΠΉ ΠΈ Π½ΠΈΠ·ΠΊΠΎΠΉ ΡΠΊΠΎΡΠΎΡΡΡΠΌΠΈ ΠΊΠΎΡΡΠ½ΠΎΠ³ΠΎ ΠΎΠ±ΠΌΠ΅Π½Π° ΠΊΠ°ΠΊ Π² ΠΏΠΎΡΡΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π°Π»ΡΠ½ΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅, ΡΠ°ΠΊ ΠΈ ΠΏΠΎΡΠ»Π΅ ΠΎΠ²Π°ΡΠΈΠΎΡΠΊΡΠΎΠΌΠΈΠΈ Π½Π΅ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½ΠΎ. Π½Π΅ΡΠΌΠΎΡΡΡ Π½Π° ΠΎΠΆΠΈΠ΄Π°Π΅ΠΌΡΡ ΡΠ²ΡΠ·Ρ Π³Π΅Π½Π° ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ° ΠΊΠ°Π»ΡΡΠΈΡΠΎΠ½ΠΈΠ½Π° Ρ ΡΠΈΡΠΊΠΎΠΌ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·Π° Π² ΠΏΠΎΡΡΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π°Π»ΡΠ½ΠΎΠΌ ΠΏΠ΅ΡΠΈΠΎΠ΄Π΅, Π½Π°ΠΌΠΈ Π½Π΅ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΎ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΡ
Π΄Π°Π½Π½ΡΡ
, ΡΠΊΠ°Π·ΡΠ²Π°ΡΡΠΈΡ
Π½Π° ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΡΡΡΡ ΡΠΎΠ»Ρ Π΄Π°Π½Π½ΠΎΠ³ΠΎ Π³Π΅Π½Π° Π² ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ ΠΊΠΎΡΡΠ½ΡΡ
ΠΏΠΎΡΠ΅ΡΡ ΠΊΠ°ΠΊ Π² ΠΏΠΎΡΡΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π΅, ΡΠ°ΠΊ ΠΈ Ρ ΠΆΠ΅Π½ΡΠΈΠ½ ΠΏΠΎΡΠ»Π΅ Π±ΠΈΠ»Π°ΡΠ΅ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΎΠ²Π°ΡΠΈΠΎΡΠΊΡΠΎΠΌΠΈΠΈ
VENOUS THROMBOEMBOLISM IN RELATION TO OVARIAN HYPERSTIMULATION SYNDROME: AN APPROACH TO DETERMINING THE LOW-MOLECULAR-WEIGHT-HEPARIN DOSES AND ACTIVITY
Ovarian hyperstimulation syndrome (OHSS) is a relatively common complication of ovarian stimulation. The pathophysiology of OHSS is characterised by increased capillary permeability. As a consequence of this, there is a fluid shift into third-space causing hemoconcentration, it may contribute to hypercoagulable state, with increased riskof venous thromboembolism. The article presents modern data on prevention of thromboembolic complication in OHSS patients with special focus on dosage and duration of thromboprophylaxis
EFFECTS OF INSULIN-LIKE GROWTH FACTOR TYPE I ON BONE REMODELING IN PHYSIOLOGICAL PREGNANCY AND NORMAL LEVELS OF VITAMIN D
During pregnancy the levels of IGF-I increase and in III trimester exceed greatly the values of I trimester. Its significant increase is noted from 22-24 weeks of pregnancy. Correlation analysis revealed a moderate negative correlation between the level of IGF-I in II trimester and distal forearm BMD (r = -0,35, p<0,5). Also a moderate positive correlation between the level of IGF-I and a marker of bone synthesis osteocalcin in the II and III trimesters of pregnancy was revealed (r = 0,46, p <0,05 and r = 0,41, p<0,05, respectively). Conclusions: IGF-I effects bone remodeling of long bones during pregnancy. It is probable that under the influence of IGF-I synthesis of bone matrix is increased, which in the presence of low calcium intake may be associated with reduced BMD at these bone sites
A Randomised, Controlled Study of Different Glycaemic Targets during Gestational Diabetes Treatment: Effect on the Level of Adipokines in Cord Blood and ANGPTL4 Expression in Human Umbilical Vein Endothelial Cells
Our aim was to study the expression of adipokine-encoding genes (leptin, adiponectin, and angiopoietin-like protein 4 (ANGPTL4)) in human umbilical vein endothelial cells (HUVECs) and adipokine concentration in cord blood from women with gestational diabetes mellitus (GDM) depending on glycaemic targets. GDM patients were randomised to 2 groups per target glycaemic levels: GDM1 (tight glycaemic targets, fasting blood glucoseβ<β5.1βmmol/L and <7.0βmmol/L postprandial, N=20) and GDM2 (less tight glycaemic targets, <5.3βmmol/L and <β7.8βmmol/L, respectively, N=21). The control group included 25 women with normal glucose tolerance. ANGPTL4 expression was decreased in the HUVECs from GDM patients versus the control group (23.11βΒ±β5.71, 21.47βΒ±β5.64, and 98.33βΒ±β20.92, for GDM1, GDM2, and controls; p<0.001) with no difference between GDM1 and GDM2. The level of adiponectin gene expression was low and did not differ among the groups. Leptin gene expression was undetectable in HUVECs. In cord blood, leptin/adiponectin ratio (LAR) was increased in GDM2 compared to controls and GDM1 (p=0.038) and did not differ between GDM1 and controls. Tight glycaemic targets were associated with normalisation of increased LAR in the cord blood. ANGPTL4 expression was downregulated in HUVECs of newborns from GDM mothers and was not affected by the intensity of glycaemic control